TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00923962
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-40 microgram/minute
Study: NCT01045486
Drug: ATP mixed probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
Study: NCT01045486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
Study: NCT01640002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
Study: NCT03099304
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT03876717
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo tablets over-encapsulated with DB caps AAA
Study: NCT01718288
Drug: Standard Treatment (aspirin.....),
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
Study: NCT01428297
Drug: BPR277 ointment (controlled application)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428297
Drug: Placebo (Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428297
Drug: BPR277 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428297
Drug: BPR277
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00126646
Drug: BL22 immunotoxin
Normalized name: hepatitis B immunoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00503750
Drug: ABI-007 (Abraxane)
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
Study: NCT04068207
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab. Minocycline 100mg po per day for 12 months
Study: NCT02589340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT02489435
Drug: VM-1500
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM-1500
Study: NCT02489435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02971423
Drug: ETX2514
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02971423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo infusion
Study: NCT01251315
Drug: Placebo low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Study: NCT01251315
Drug: N Acetyl cysteine, 600mg (low dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
Study: NCT01708798
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01708798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01251315
Drug: Placebo (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Study: NCT01251315
Drug: N Acetyl cysteine, 1200mg (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
Study: NCT01251315
Drug: FT061452, 6000mg high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
Study: NCT02514278
Drug: Neoadjuvant chemotherapy Folfirinox, 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2
Study: NCT02514278
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600 mg/m2 daily 5 days/7
Study: NCT00405535
Drug: glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01444417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by subcutaneous injection
Study: NCT00814905
Drug: ampicillin gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
Study: NCT00814905
Drug: Ampicillin gentamicin clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
Study: NCT00814905
Drug: ampicillin gentamicin clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
Study: NCT02837900
Drug: TPX-100 200 mg 4 times weekly for 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ea. subject will received active TPX-100 200mg in the Left knee
Study: NCT02837900
Drug: TPX-100 200 mg 4 times weekly for 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPX-100 100mg Right
Study: NCT03094182
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
Study: NCT01831700
Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study: NCT01831700
Drug: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study: NCT03628040
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be injected in the erector spinae plane
Study: NCT00388661
Drug: Melatonin tablet 3 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin tablet 3 mg once daily
Study: NCT00388661
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00237770
Drug: N-Nitro L-arginine-methylester (L-NAME)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study: NCT00026234
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00989001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT00818805
Drug: Placebo (Olopatadine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in contralateral eye
Study: NCT00818805
Drug: Placebo (Tranilast)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in contralateral eye
Study: NCT01179334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks
Study: NCT02626299
Drug: Docosahexaenoic acid - 800mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
Study: NCT02626299
Drug: Docosahexaenoic acid - 200mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive 1-capsule containing 200 mg DHA/d.
Study: NCT02352090
Drug: Ethinyl estradiol / dienogest
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally for 9 weeks, continuous use
Study: NCT02352090
Drug: Estradiol valerate / dienogest
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally for 9 weeks, continuous use
Study: NCT00193128
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
Study: NCT01654328
Drug: Isotonic saline intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
Study: NCT00468910
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02655029
Drug: Perindopril/Indapamide/Amlodipine fixed dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose selection is based on investigators management.
Study: NCT03908333
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25, 37.5, 56.25 or 75 grams/m2
Study: NCT01576952
Drug: ISV-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac in DuraSite
Study: NCT01847872
Drug: IPV IM Device
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01847872
Drug: IPV ID Device
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00111709
Drug: Comparator: placebo / Duration of Treatment - 1 day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00838253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo continuous i.v. infusion for 24 hours
Study: NCT04673214
Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Study: NCT00529659
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily, 6 month treatment period
Study: NCT01823133
Drug: rosuvastatin only
Normalized name: Rosuvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20mg qd on day 1\~7
Study: NCT01823133
Drug: gemigliptin and rosuvastatin
Normalized name: gemigliptin and rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
Study: NCT01503749
Drug: G-colony stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
Study: NCT04673214
Drug: Azithromycin / Ribaroxaban / Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Study: NCT04321031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03876210
Drug: PK101-001, PK101-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: coadministration
Study: NCT03684863
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: observation
Study: NCT00555412
Drug: D - inhaled placebo q 4 h x 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo aerosol inhalation (0 mg total)
Study: NCT02497716
Drug: Rivaroxaban (Xarelto, BAY59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of reconstituted rivaroxaban granules
Study: NCT01169103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
Study: NCT00217841
Drug: Aurograb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03061227
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Study: NCT02531113
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01582815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
Study: NCT01040494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
Study: NCT04622111
Drug: CPL207280
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Study: NCT04622111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT04072926
Drug: BioRoot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influence of biomaterial BioRoot on periapical healing
Study: NCT04472611
Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
Study: NCT03494946
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: May include chemotherapy, TACE, SIRT or other available treatment options.
Study: NCT02531152
Drug: SAR366234
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648011
Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Normalized name: hydrochlorothiazide / quinapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fed
Study: NCT00648011
Drug: Accuretic™ Tablets 20 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fed
Study: NCT02246049
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03662958
Drug: Lutrate
Normalized name: Lutrate Depot 3-Month 22.5mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: a novel leuprolide acetate 3.75mg depot
Study: NCT00303823
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00010400
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01512199
Drug: U3-1287
Approvals — FDA: no, EMA: no, PMDA: no
Description: U3-1287: 18 mg/kg administered intravenously once every three weeks
Study: NCT01512199
Drug: U3-1287
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
Study: NCT01512199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
Study: NCT02343042
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT01003158
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Oral bid
Study: NCT00325715
Drug: AGN 201904
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733875
Drug: CC-220 0.03 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of CC-220 0.03 mg will be administered orally once a day.
Study: NCT01733875
Drug: CC-220 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of CC-220 0.1 mg will be administered orally once a day.
Study: NCT01733875
Drug: CC-220 0.3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of CC-220 0.3 mg will be administered orally once a day.
Study: NCT02300844
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated.
Study: NCT02300844
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
Study: NCT01733875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo will be administered orally once a day.
Study: NCT01116180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule matching the active comparator. Given for 7 days once daily.
Study: NCT02201043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01555099
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhaled
Study: NCT01555099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhaled
Study: NCT00003868
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003868
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00955825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
Study: NCT00478595
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT00478595
Drug: Anti-diabetic monotherapy
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
Study: NCT03282461
Drug: ABY-029
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
Study: NCT04950933
Drug: Huolingshengji Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
Study: NCT00537602
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04291846
Drug: SHR1459 fasted in P1, high-fat diet in P2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
Study: NCT04291846
Drug: SHR1459 high-fat diet in P1, fasted in P2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
Study: NCT00469040
Drug: GW642444M for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: M salt
Study: NCT00391846
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00391846
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00391846
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00391846
Drug: HF treatment according to Swedish guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03394196
Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
Study: NCT03394196
Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
Study: NCT02914639
Drug: SF0166 Topical Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01960140
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01904071
Drug: IVMS (IV Morphine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Morphine
Study: NCT02819414
Drug: Paracetamol drops
Normalized name: Soul Pattinson Colour Free Paracetamol Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
Study: NCT00818454
Drug: Combivent CFC MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00818454
Drug: Respimat Combivent
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01867216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT01867216
Drug: LY2922470
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT00693121
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days